Suchergebnisse
Suchergebnisse:
1. Juli 2024 · A meta-analysis by Fleischmann (Fleischmann-Struzek et al. 2020) in 2020 revealed an in-hospital incidence rate of sepsis worldwide of 189/100,000 person-years, with a mortality rate of approximately 26.7%. Five domestic studies reported sepsis incidence rates in the ICU ranging from 20.6% to 50.8%.
12. Juni 2024 · The primary end point of the study was to establish the maximum tolerated dose and recommended phase II dose (RP2D). The 20 patients enrolled comprised a heavily pretreated population: 95% had received prior platinum-based chemotherapy, 40% irinotecan, and 20% PARP inhibitors.
17. Juni 2024 · Antibody–drug conjugates have demonstrated efficacy against various types of tumors, including breast cancer. Ado-trastuzumab emtansine is presently the only approved ADC for the treatment of breast cancer in the early setting, while several ADCs are now approved for metastatic breast cancer.
26. Juni 2024 · Enibarcimab: AdrenoMed AG Enibarcimab (HAM8101; former name: Adrecizumab) a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality ...
28. Juni 2024 · Monoklonale Antikörper sind Antikörper, die von einer Zelllinie ("Zellklon") produziert werden, die auf einen einzigen B-Lymphozyten zurückgeht.
1. Juli 2024 · Expert opinion: ADZ is the first humanized antibody directed against ADM. The main interest of ADZ is its potential use as a 'biomarker-guided therapy' in septic patients with high circulating ADM. ADZ is increasingly seen as a potential adjunct therapy to restore endothelial function in septic shock.
21. Juni 2024 · Enibarcimab: AdrenoMed AG Enibarcimab (HAM8101; former name: Adrecizumab) a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality ...
